{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:40:51Z","timestamp":1792449651364,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013365","name":"Sichuan University West China Hospital","doi-asserted-by":"publisher","award":["ZYGD23035"],"award-info":[{"award-number":["ZYGD23035"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"Sichuan University West China Hospital","doi-asserted-by":"publisher","award":["ZYYC23008"],"award-info":[{"award-number":["ZYYC23008"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22377086"],"award-info":[{"award-number":["22377086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118212","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T20:09:30Z","timestamp":1759262970000},"page":"118212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis and biological evaluation of 8-phenylquinazolin-2-amine derivatives as FLT3 covalent inhibitors targeting cysteine 828 in the ATP pocket"],"prefix":"10.1016","volume":"301","author":[{"given":"Wei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongmin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0246-8761","authenticated-orcid":false,"given":"Zhihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmech.2025.118212_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000536152","article-title":"Pathophysiology of acute myeloid leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ejmech.2025.118212_bib2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118212_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2025.102526","article-title":"Therapeutic hurdles in acute myeloid leukemia: leukemic stem cells, inflammation and immune dysfunction","volume":"82","author":"Wang","year":"2025","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118212_bib4","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"Br. Med. J."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118212_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118212_bib6","first-page":"588","article-title":"Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells","volume":"10","author":"Drexler","year":"1996","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118212_bib7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-Like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118212_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3324\/haematol.2019.240754","article-title":"Potential targeting of FLT3 acute myeloid leukemia","volume":"106","author":"Ambinder","year":"2021","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.ejmech.2025.118212_bib9","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118212_bib10","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(23)00617-7","article-title":"FLT3-mutated acute myeloid leukaemia: a new opportunity","volume":"401","author":"Przespolewski","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118212_bib11","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118212_bib12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia","volume":"106","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118212_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2025.118212_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118212_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.ejmech.2025.118212_bib16","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118212_bib17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/17474086.2017.1397510","article-title":"Midostaurin\/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia","volume":"10","author":"Luskin","year":"2017","journal-title":"Expert Rev. Hematol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118212_bib18","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40265-017-0779-0","article-title":"Midostaurin: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118212_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","article-title":"Gilteritinib: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118212_bib20","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/jcm12113647","article-title":"Gilteritinib: the story of a proceeding success into hard-to-treat FLT3-Mutated AML patients","volume":"12","author":"Molica","year":"2023","journal-title":"J. Clin. Med."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118212_bib21","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.3390\/cancers14174315","article-title":"Overcoming resistance: FLT3 inhibitors past, present, future and the challenge of cure","volume":"14","author":"Capelli","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118212_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.118212_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118212_bib24","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.ejmech.2025.118212_bib25","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.3390\/jcm12206429","article-title":"A review of FLT3 kinase inhibitors in AML","volume":"12","author":"Negotei","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118212_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114348","article-title":"Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors","volume":"183","author":"Marensi","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118212_bib27","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118212_bib28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \"Gatekeeper\" F691L mutation with PLX3397","volume":"5","author":"Smith","year":"2015","journal-title":"Cancer Discov."},{"issue":"43","key":"10.1016\/j.ejmech.2025.118212_bib29","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.118212_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116386","article-title":"Recent progress in covalent warheads for in vivo targeting of endogenous proteins","volume":"47","author":"Shindo","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118212_bib31","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chem. Soc. Rev."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118212_bib32","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/bloodadvances.2023010619","article-title":"A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia","volume":"8","author":"Levis","year":"2024","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118212_bib33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118212_bib34","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118212_bib35","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1021\/acs.jmedchem.8b01714","article-title":"Virtual screening identifies irreversible FMS-Like tyrosine kinase 3 inhibitors with activity toward resistance-conferring mutations","volume":"62","author":"Bensinger","year":"2019","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118212_bib36","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1073\/pnas.0600445103","article-title":"Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides","volume":"103","author":"Schirmer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"23","key":"10.1016\/j.ejmech.2025.118212_bib37","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1016\/j.bmc.2014.10.006","article-title":"Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core","volume":"22","author":"Xu","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118212_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111710","article-title":"Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases","volume":"184","author":"Baska","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118212_bib39","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1248\/bpb.b21-00579","article-title":"Discover novel covalent inhibitors targeting FLT3 through hybrid virtual screening strategy","volume":"44","author":"Hu","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2025.118212_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116937","article-title":"Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia","volume":"70","author":"Kang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118212_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ddr.22032","article-title":"Discovery of 4-(4-aminophenyl)-6-phenylisoxazolo[3,4-b]pyridine-3-amine derivatives as novel FLT3 covalent inhibitors for the intervention of acute myeloid leukemia","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev. Res."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118212_bib42","doi-asserted-by":"crossref","first-page":"11894","DOI":"10.1021\/acs.jmedchem.5c00698","article-title":"Discovery of a potent FLT3 inhibitor (E)-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1H-indazol-6-yl)pyridin-2-amine for the treatment of acute myeloid leukemia with multiple FLT3 mutations","volume":"68","author":"Liu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118212_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/srep11702","article-title":"Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification","volume":"5","author":"Ke","year":"2015","journal-title":"Sci. Rep."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:19:45Z","timestamp":1773141585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S0223523425009778"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118212","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of 8-phenylquinazolin-2-amine derivatives as FLT3 covalent inhibitors targeting cysteine 828 in the ATP pocket","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118212"}}